Nonetheless, industry experts feel that government pressure to lower the cost of prescription drugs is simply par for the course and that drug companies will simply move forward even if prices do eventually come down as a result of governmental regulation.

“Every now and then senior company executives decide that there is so much anger and pressure, and they will show they are good citizens” by promising to restrain prices, said Donald Light, health policy professor at Rowan University’s School of Osteopathic Medicine in New Jersey. “But it only happens for a year or two.”

If history repeats itself and drug prices continue to rise in “business as usual” fashion, then PILL could stand to benefit–the difference being that it could benefit three times over with respect to its other pharma ETF peers–and that could rid any headaches investors are experiencing with their portfolios. PILL is up 6.36% year-to-date per Yahoo! Finance performance numbers.

For more market trends in pharma ETFs, click here.